A 27-year-old woman with Kallmann syndrome (congenital GnRH deficiency) desires pregnancy. She has been on estrogen-progesterone replacement for bone health. Her physician plans to switch her to pulsatile GnRH therapy. After 6 weeks of treatment, labs show: LH 4 mIU/mL, FSH 5 mIU/mL, estradiol 120 pg/mL. Ultrasound shows a 16mm dominant follicle. Evaluate and synthesize the physiologic response to determine the appropriate next intervention for ovulation induction.
Q2
A 30-year-old woman at 28 weeks gestation with gestational diabetes managed with insulin presents with decreased fetal movement. Fetal monitoring shows category II tracing. Umbilical artery Doppler shows absent end-diastolic flow. Her glucose control has been suboptimal (HbA1c 7.8%). Maternal blood pressure is normal. Synthesize the pathophysiologic relationship between her metabolic condition and the Doppler findings to determine the primary mechanism.
Q3
A 42-year-old woman with previously regular 28-day cycles now reports cycles varying from 24-35 days over the past year. Day 3 labs show: FSH 18 mIU/mL (normal: 3-10), LH 10 mIU/mL, estradiol 35 pg/mL, AMH 0.4 ng/mL (normal age 40-44: 0.5-2.5). She has three children and desires no future pregnancies but wants to understand her physiology. Evaluate these findings and synthesize the underlying pathophysiologic process.
Q4
A 38-year-old G3P2 woman at 39 weeks gestation presents in active labor. She has a history of postpartum hemorrhage with her second delivery requiring transfusion. After delivery of the infant, the placenta is delivered intact 8 minutes later. Her obstetrician administers oxytocin. Ten minutes postpartum, she has moderate vaginal bleeding. Analyze the physiologic mechanisms and determine the most likely cause of bleeding.
Q5
A 26-year-old woman with regular menses undergoes hormonal evaluation on day 3 of her cycle: FSH 8 mIU/mL, LH 6 mIU/mL, estradiol 45 pg/mL. On day 14, repeat testing shows: FSH 10 mIU/mL, LH 42 mIU/mL, estradiol 250 pg/mL. On day 21: progesterone 16 ng/mL, estradiol 150 pg/mL. Analyze this hormonal pattern to identify the physiologic mechanism driving the day 14 LH surge.
Q6
A 29-year-old woman at 10 weeks gestation develops severe hyperemesis gravidarum. Ultrasound reveals a complete hydatidiform mole. Her serum hCG is 500,000 mIU/mL. She undergoes suction curettage. Two weeks post-procedure, her hCG is 50,000 mIU/mL. Four weeks post-procedure, it is 45,000 mIU/mL. Analyze these findings to determine the most appropriate next step.
Q7
A 35-year-old woman undergoes in vitro fertilization with embryo transfer on day 3 post-retrieval. Her ovarian stimulation protocol included recombinant FSH and GnRH antagonist, with hCG trigger 36 hours before retrieval. On the day of transfer (day 3), what would be the expected dominant hormone maintaining the endometrium, and what is its primary source?
Q8
A 24-year-old nulliparous woman presents with secondary amenorrhea for 6 months. She is a competitive marathon runner training 70 miles per week with 12% body fat. Labs show: LH 1.2 mIU/mL (normal follicular phase: 2-10), FSH 2.1 mIU/mL (normal: 3-10), estradiol 15 pg/mL (normal follicular: 30-100), prolactin 14 ng/mL (normal: <25), TSH 2.1 mIU/L. Apply these findings to determine the mechanism of her amenorrhea.
Q9
A 32-year-old woman at 8 weeks gestation presents with nausea and vomiting. Laboratory studies show: hCG 150,000 mIU/mL (expected for gestational age: 50,000-100,000 mIU/mL), TSH 0.1 mIU/L (normal: 0.4-4.0), free T4 1.8 ng/dL (normal: 0.8-1.8). She has no personal or family history of thyroid disease. Apply your understanding of pregnancy hormones to explain these findings.
Q10
A 28-year-old woman presents to the clinic for evaluation of infertility. Her menstrual cycles have been regular every 28 days. She reports using basal body temperature charting, which shows a biphasic pattern with temperature elevation occurring around day 14. Serum progesterone is measured on day 21 of her cycle and is found to be 18 ng/mL (normal luteal phase >10 ng/mL). Based on this information, what is the most likely status of her ovulatory function?
Reproductive Physiology Indian Medical PG Practice Questions and MCQs
Question 1: A 27-year-old woman with Kallmann syndrome (congenital GnRH deficiency) desires pregnancy. She has been on estrogen-progesterone replacement for bone health. Her physician plans to switch her to pulsatile GnRH therapy. After 6 weeks of treatment, labs show: LH 4 mIU/mL, FSH 5 mIU/mL, estradiol 120 pg/mL. Ultrasound shows a 16mm dominant follicle. Evaluate and synthesize the physiologic response to determine the appropriate next intervention for ovulation induction.
A. Switch to gonadotropin therapy with recombinant FSH and LH
B. Administer exogenous hCG to trigger ovulation and time intercourse (Correct Answer)
C. Increase GnRH pulse frequency to stimulate endogenous LH surge
D. Add clomiphene citrate to augment endogenous gonadotropin release
E. Continue current GnRH dosing and monitor for spontaneous LH surge
Explanation: ***Administer exogenous hCG to trigger ovulation and time intercourse***
- The patient has achieved a **dominant follicle (16mm)** and appropriate **estradiol levels**, indicating that the follicular phase was successful under pulsatile GnRH therapy.
- In **Kallmann syndrome**, the absence of GnRH neurons means the body cannot generate the spontaneous **LH surge** required for ovulation; **exogenous hCG** acts as an LH analog to trigger the final maturation and release of the oocyte.
*Switch to gonadotropin therapy with recombinant FSH and LH*
- This intervention is unnecessary because the patient is already responding well to **pulsatile GnRH**, as evidenced by rising **estradiol** and follicle growth.
- **Gonadotropins** are an alternative for ovulation induction but are more expensive and carry a higher risk of **ovarian hyperstimulation syndrome** compared to GnRH pumps.
*Increase GnRH pulse frequency to stimulate endogenous LH surge*
- While pulse frequency changes naturally during the cycle, an automated pump maintaining a fixed pulsatile rhythm cannot simulate the massive **GnRH surge** needed to trigger ovulation in a patient with no endogenous GnRH neurons.
- Simply increasing frequency will not overcome the primary defect of **GnRH neuron migration** failure inherent in Kallmann syndrome.
*Add clomiphene citrate to augment endogenous gonadotropin release*
- **Clomiphene citrate** works by blocking estrogen receptors in the **hypothalamus** to increase endogenous GnRH; this is ineffective in Kallmann syndrome because the GnRH-producing neurons are absent.
- This medication requires a functional **hypothalamic-pituitary-ovarian axis**, which is structurally compromised in this patient.
*Continue current GnRH dosing and monitor for spontaneous LH surge*
- A spontaneous surge is highly unlikely in **Kallmann syndrome** because the physiological feedback loop that triggers a surge of GnRH from the hypothalamus is broken.
- Monitoring alone would likely lead to a **persistent follicle** or follicular atresia rather than successful ovulation induction.
Question 2: A 30-year-old woman at 28 weeks gestation with gestational diabetes managed with insulin presents with decreased fetal movement. Fetal monitoring shows category II tracing. Umbilical artery Doppler shows absent end-diastolic flow. Her glucose control has been suboptimal (HbA1c 7.8%). Maternal blood pressure is normal. Synthesize the pathophysiologic relationship between her metabolic condition and the Doppler findings to determine the primary mechanism.
A. Placental hypertrophy from fetal macrosomia compressing umbilical cord
B. Uteroplacental insufficiency from diabetes-induced vasculopathy affecting spiral arteries (Correct Answer)
C. Fetal polycythemia from chronic hypoxia increasing blood viscosity
D. Maternal ketoacidosis causing direct fetal myocardial depression
E. Maternal hyperglycemia causing fetal hyperinsulinemia and increased oxygen consumption
Explanation: ***Uteroplacental insufficiency from diabetes-induced vasculopathy affecting spiral arteries***
- **Absent end-diastolic flow (AEDF)** in the umbilical artery signifies extremely high **vascular resistance** within the placenta, typically due to **decidual vasculopathy** and remodeling of spiral arteries.
- In patients with poorly controlled diabetes (HbA1c 7.8%), **chronic hyperglycemia** leads to basement membrane thickening and endothelial dysfunction, which impairs placental perfusion and oxygen delivery.
*Placental hypertrophy from fetal macrosomia compressing umbilical cord*
- While **placental hypertrophy** occurs in gestational diabetes, it does not exert mechanical pressure on the umbilical cord sufficient to cause **AEDF**.
- AEDF is a hemodynamic marker of **placental resistance**, whereas cord compression typically presents as **variable decelerations** on fetal monitoring.
*Fetal polycythemia from chronic hypoxia increasing blood viscosity*
- **Fetal polycythemia** is a secondary compensatory response to **chronic hypoxia** triggered by placental insufficiency, rather than the primary cause of AEDF.
- Increased **blood viscosity** can affect flow, but the fundamental pathology leading to the loss of diastolic flow is the destruction of the **villous vascular tree**.
*Maternal ketoacidosis causing direct fetal myocardial depression*
- **Diabetic ketoacidosis (DKA)** is an acute metabolic emergency that can cause fetal distress, but there is no evidence of **acidosis** or ketosis in this clinical presentation.
- **Myocardial depression** would likely manifest as fetal bradycardia or loss of variability, but it is not the classic mechanism for causing **umbilical artery AEDF**.
*Maternal hyperglycemia causing fetal hyperinsulinemia and increased oxygen consumption*
- **Fetal hyperinsulinemia** increases metabolic rate and oxygen demand, which contributes to **fetal hypoxia**, but it doesn't directly increase placental **vascular resistance**.
- This mechanism explains **macrosomia** and stillbirth risks, but **AEDF** reflects a structural/functional failure of the **maternal-fetal interface** (vasculopathy).
Question 3: A 42-year-old woman with previously regular 28-day cycles now reports cycles varying from 24-35 days over the past year. Day 3 labs show: FSH 18 mIU/mL (normal: 3-10), LH 10 mIU/mL, estradiol 35 pg/mL, AMH 0.4 ng/mL (normal age 40-44: 0.5-2.5). She has three children and desires no future pregnancies but wants to understand her physiology. Evaluate these findings and synthesize the underlying pathophysiologic process.
A. Hypothalamic dysfunction from chronic stress affecting GnRH pulsatility
B. Primary ovarian insufficiency requiring hormone replacement therapy
C. Polycystic ovary syndrome with age-related metabolic changes
D. Autoimmune oophoritis causing accelerated follicular atresia
E. Normal perimenopausal transition with declining ovarian reserve and altered follicular dynamics (Correct Answer)
Explanation: ***Normal perimenopausal transition with declining ovarian reserve and altered follicular dynamics***
- The patient exhibits classic clinical signs of **perimenopause**, characterized by **cycle length variability** and a **diminished ovarian reserve** evidenced by low **AMH** and elevated **Day 3 FSH**.
- Elevated FSH occurs because fewer follicles are available to produce **inhibin B**, leading to decreased **negative feedback** on the pituitary gland and accelerated follicular recruitment.
*Hypothalamic dysfunction from chronic stress affecting GnRH pulsatility*
- Functional **hypothalamic amenorrhea** typically presents with **low or low-normal FSH** and LH due to suppressed GnRH pulsatility, which contradicts this patient's elevated FSH.
- Stress-induced dysfunction usually leads to **amenorrhea** or significantly prolonged cycles rather than the fluctuating short and long cycles seen here.
*Primary ovarian insufficiency requiring hormone replacement therapy*
- **Primary ovarian insufficiency (POI)** is defined by the loss of ovarian function **before age 40**, whereas this patient is 42 years old.
- Diagnostic criteria for POI involve **FSH levels >40 mIU/mL** on two occasions, which is significantly higher than this patient's level of 18 mIU/mL.
*Polycystic ovary syndrome with age-related metabolic changes*
- **PCOS** generally presents with **oligomenorrhea** and hyperandrogenism, and diagnostic labs typically show a **reversed LH:FSH ratio** (LH > FSH).
- Patients with PCOS often have **elevated AMH** levels due to an abundance of small antral follicles, which is the opposite of this patient's low AMH of 0.4 ng/mL.
*Autoimmune oophoritis causing accelerated follicular atresia*
- **Autoimmune oophoritis** is a rare cause of primary ovarian insufficiency that often presents with more **abrupt ovarian failure** and specific adrenal autoantibodies.
- This patient's presentation is more consistent with the **natural physiological progression** of reproductive aging expected for her 40s.
Question 4: A 38-year-old G3P2 woman at 39 weeks gestation presents in active labor. She has a history of postpartum hemorrhage with her second delivery requiring transfusion. After delivery of the infant, the placenta is delivered intact 8 minutes later. Her obstetrician administers oxytocin. Ten minutes postpartum, she has moderate vaginal bleeding. Analyze the physiologic mechanisms and determine the most likely cause of bleeding.
A. Retained placental fragments preventing uterine contraction
B. Coagulopathy from amniotic fluid embolism
C. Uterine atony despite oxytocin administration (Correct Answer)
D. Vaginal or cervical laceration from delivery
E. Placenta accreta with incomplete separation
Explanation: ***Uterine atony despite oxytocin administration***
- **Uterine atony** is the most common cause of **postpartum hemorrhage (PPH)**, occurring when the myometrium fails to contract and compress the **spiral arteries** after delivery.
- Risk factors include **multiparity** and a **prior history of PPH**, which can lead to atony despite the prophylactic use of **oxytocin**.
*Retained placental fragments preventing uterine contraction*
- This is unlikely because the **placenta was delivered intact**, suggesting no mechanical interference with uterine contraction.
- **Retained fragments** typically cause a **boggy uterus** and persistent bleeding but are ruled out by an inspection of the placental membranes.
*Coagulopathy from amniotic fluid embolism*
- **Amniotic fluid embolism** is a rare, life-threatening emergency characterized by **sudden cardiovascular collapse**, respiratory distress, and **DIC**.
- There is no clinical evidence of **hemodynamic instability** or respiratory failure aside from the moderate bleeding described.
*Vaginal or cervical laceration from delivery*
- **Lacerations** typically present with continuous bleeding despite a **firm, well-contracted uterus**.
- The scenario points toward a failure of the physiologic contraction mechanism rather than **birth canal trauma**.
*Placenta accreta with incomplete separation*
- **Placenta accreta** involves the abnormal attachment of the placenta directly to the **myometrium**, usually resulting in failure of the placenta to deliver.
- In this case, the placenta was **delivered intact** and relatively quickly (8 minutes), which excludes accreta or incomplete separation.
Question 5: A 26-year-old woman with regular menses undergoes hormonal evaluation on day 3 of her cycle: FSH 8 mIU/mL, LH 6 mIU/mL, estradiol 45 pg/mL. On day 14, repeat testing shows: FSH 10 mIU/mL, LH 42 mIU/mL, estradiol 250 pg/mL. On day 21: progesterone 16 ng/mL, estradiol 150 pg/mL. Analyze this hormonal pattern to identify the physiologic mechanism driving the day 14 LH surge.
A. Positive feedback from sustained high estradiol levels on the hypothalamic-pituitary axis (Correct Answer)
B. GnRH-independent pulsatile LH secretion from pituitary gonadotrophs
C. Decreased progesterone-mediated negative feedback allowing LH release
D. Direct stimulation of pituitary by inhibin B from dominant follicle
E. Decreased negative feedback from declining FSH concentrations
Explanation: ***Positive feedback from sustained high estradiol levels on the hypothalamic-pituitary axis***
- The mid-cycle **LH surge** is triggered when **estradiol** levels remain above a threshold (>200 pg/mL) for approximately 36 to 48 hours, as evidenced by the day 14 level of 250 pg/mL.
- This sustained peak causes a shift from negative feedback to **positive feedback**, resulting in increased **GnRH pulse frequency** and enhanced pituitary sensitivity to GnRH.
*GnRH-independent pulsatile LH secretion from pituitary gonadotrophs*
- The LH surge is highly dependent on **GnRH stimulation**; it does not occur spontaneously or independently from the hypothalamus.
- Pulsatile GnRH secretion is required to maintain the synthesis and release of both **FSH and LH** throughout the cycle.
*Decreased progesterone-mediated negative feedback allowing LH release*
- Progesterone is typically low during the **follicular phase**; it only rises significantly after ovulation as seen in the day 21 lab (16 ng/mL).
- Progesterone actually participates in the **negative feedback** loop during the luteal phase to suppress further LH and FSH release.
*Direct stimulation of pituitary by inhibin B from dominant follicle*
- **Inhibin B** is primarily involved in the **negative feedback** suppression of **FSH** during the early to mid-follicular phase.
- It does not serve as the primary physiologic trigger for the massive release of **LH** at mid-cycle.
*Decreased negative feedback from declining FSH concentrations*
- While FSH does decline slightly in the late follicular phase due to **estradiol/inhibin** negative feedback, this decline does not trigger the LH surge.
- The surge is an active, **positive feedback event** stimulated by rising estradiol, not a passive response to falling FSH levels.
Question 6: A 29-year-old woman at 10 weeks gestation develops severe hyperemesis gravidarum. Ultrasound reveals a complete hydatidiform mole. Her serum hCG is 500,000 mIU/mL. She undergoes suction curettage. Two weeks post-procedure, her hCG is 50,000 mIU/mL. Four weeks post-procedure, it is 45,000 mIU/mL. Analyze these findings to determine the most appropriate next step.
A. Continue weekly hCG monitoring as normal decline is occurring
B. Perform hysterectomy for definitive treatment
C. Repeat suction curettage for retained molar tissue
D. Initiate single-agent methotrexate chemotherapy for gestational trophoblastic neoplasia (Correct Answer)
E. Begin multi-agent chemotherapy with EMA-CO regimen
Explanation: ***Initiate single-agent methotrexate chemotherapy for gestational trophoblastic neoplasia***
- The patient meets the diagnostic criteria for **Gestational Trophoblastic Neoplasia (GTN)** because her **hCG levels have plateaued** (less than 10% change over three consecutive weekly measurements).
- **Single-agent chemotherapy** with **methotrexate** or actinomycin D is the standard first-line treatment for **low-risk GTN** (FIGO score < 7), offering a high cure rate while preserving fertility.
*Continue weekly hCG monitoring as normal decline is occurring*
- A normal post-evacuation decline should show a **50% decrease every week**; a plateau specifically indicates **malignant transformation** or persistent disease.
- Waiting further delays necessary treatment for **postmolar GTN**, which increases the risk of local invasion or distant metastasis.
*Perform hysterectomy for definitive treatment*
- **Hysterectomy** is generally reserved for patients who have completed childbearing or those with **chemoresistant disease**.
- At age 29, preserving **reproductive function** is a priority, and GTN is highly sensitive to medical management.
*Repeat suction curettage for retained molar tissue*
- **Repeat curettage** is not recommended as it increases the risk of **uterine perforation** and hemorrhage without addressing trophoblastic cells deep in the myometrium.
- It does not treat **micrometastatic disease**, which is likely when hCG levels fail to drop appropriately.
*Begin multi-agent chemotherapy with EMA-CO regimen*
- **Multi-agent chemotherapy** (EMA-CO) is indicated for **high-risk GTN** (FIGO score ≥ 7), which involves intensive staging and higher toxicity.
- This patient is classified as **low-risk** based on her age, recent pregnancy, and lack of documented metastases, making aggressive regimens unnecessary.
Question 7: A 35-year-old woman undergoes in vitro fertilization with embryo transfer on day 3 post-retrieval. Her ovarian stimulation protocol included recombinant FSH and GnRH antagonist, with hCG trigger 36 hours before retrieval. On the day of transfer (day 3), what would be the expected dominant hormone maintaining the endometrium, and what is its primary source?
A. Estradiol from the developing embryo
B. Estradiol from residual follicular cells
C. Progesterone from corpora lutea formed after oocyte retrieval (Correct Answer)
D. hCG from early embryonic trophoblast cells
E. Progesterone from adrenal glands under ACTH stimulation
Explanation: ***Progesterone from corpora lutea formed after oocyte retrieval***
- Following the **hCG trigger** (which mimics the natural LH surge), the granulosa and theca cells remaining in the ovary undergo **luteinization** to form multiple **corpora lutea**.
- These secondary structures secrete high levels of **progesterone** to transform the endometrium into a **secretory state**, making it receptive for the day 3 embryo transfer.
*Estradiol from the developing embryo*
- A day 3 embryo consists of only 6 to 8 cells and lacks the metabolic machinery to be the primary source of **circulating steroids**.
- While the embryo interacts with the endometrium, it does not produce the **estradiol** required to maintain the uterine lining at this stage.
*Estradiol from residual follicular cells*
- Although residual cells produce some estrogen, **progesterone** is the dominant and essential hormone required for **endometrial maintenance** and decidualization in the luteal phase.
- Strategic focus in the post-retrieval phase is on the **secretory transformation** driven by progesterone, rather than the proliferative effects of estradiol.
*hCG from early embryonic trophoblast cells*
- Endogenous **hCG production** begins only after the embryo reaches the blastocyst stage and initiates **implantation** (usually day 6 or later).
- On day 3, the embryo is still in the **cleavage stage** and has not yet developed the syncytiotrophoblast necessary to secrete significant amounts of hCG.
*Progesterone from adrenal glands under ACTH stimulation*
- While the **adrenal glands** produce small amounts of progesterone precursors, they are not a significant source for **endometrial support**.
- The **luteinized granulosa cells** in the ovary are specifically designed to produce the massive quantities of progesterone needed for a successful **IVF pregnancy**.
Question 8: A 24-year-old nulliparous woman presents with secondary amenorrhea for 6 months. She is a competitive marathon runner training 70 miles per week with 12% body fat. Labs show: LH 1.2 mIU/mL (normal follicular phase: 2-10), FSH 2.1 mIU/mL (normal: 3-10), estradiol 15 pg/mL (normal follicular: 30-100), prolactin 14 ng/mL (normal: <25), TSH 2.1 mIU/L. Apply these findings to determine the mechanism of her amenorrhea.
A. Primary ovarian insufficiency from autoimmune destruction
B. Polycystic ovary syndrome with LH/FSH ratio abnormality
C. Hypothalamic amenorrhea from energy deficit and low leptin (Correct Answer)
D. Pituitary adenoma causing hyperprolactinemia
E. Asherman syndrome from endometrial adhesions
Explanation: ***Hypothalamic amenorrhea from energy deficit and low leptin***
- This clinical scenario describes **functional hypothalamic amenorrhea (FHA)**, where excessive exercise and low body fat lead to suppressed **GnRH pulsatility** and low levels of **LH, FSH, and estradiol**.
- Chronic energy deficit and decreased adipose tissue result in low **leptin levels**, which signals the hypothalamus to downregulate the reproductive axis to conserve energy.
*Primary ovarian insufficiency from autoimmune destruction*
- This condition presents with **hypergonadotropic hypogonadism**, characterized by **elevated FSH** and LH levels due to lack of negative feedback from the ovaries.
- The patient has **low-normal gonadotropins**, which rules out ovarian failure or premature depletion of follicles.
*Polycystic ovary syndrome with LH/FSH ratio abnormality*
- PCOS typically presents with **hyperandrogenism** (e.g., hirsutism, acne) and an **increased LH/FSH ratio**, rather than the low levels seen here.
- Patients with PCOS are more likely to exhibit **menstrual irregularities** or oligomenorrhea associated with insulin resistance rather than exercise-induced hypothalamic suppression.
*Pituitary adenoma causing hyperprolactinemia*
- A prolactinoma would cause **elevated prolactin** levels, which inhibit GnRH secretion, but this patient's prolactin is within the **normal range**.
- Pituitary causes are also usually associated with other symptoms like headaches or **visual field defects** if the tumor is a macroadenoma.
*Asherman syndrome from endometrial adhesions*
- This diagnosis is unlikely in a **nulliparous woman** without a history of uterine instrumentation or intrauterine infection.
- Patients with Asherman syndrome have normal hormone levels (**ovulatory cycles**) because the pathology is structural (uterine) rather than hormonal (hypothalamic-pituitary).
Question 9: A 32-year-old woman at 8 weeks gestation presents with nausea and vomiting. Laboratory studies show: hCG 150,000 mIU/mL (expected for gestational age: 50,000-100,000 mIU/mL), TSH 0.1 mIU/L (normal: 0.4-4.0), free T4 1.8 ng/dL (normal: 0.8-1.8). She has no personal or family history of thyroid disease. Apply your understanding of pregnancy hormones to explain these findings.
A. Pre-existing Graves disease unmasked by pregnancy
B. Twin pregnancy with pathologic thyroid hormone elevation
C. hCG-mediated thyroid stimulation causing gestational thyrotoxicosis (Correct Answer)
D. Hyperemesis gravidarum with secondary hyperthyroidism
E. Thyroid adenoma with autonomous function
Explanation: ***hCG-mediated thyroid stimulation causing gestational thyrotoxicosis***
- Human chorionic gonadotropin (**hCG**) and **TSH** share a common **alpha-subunit**, allowing high levels of hCG to cross-react with and stimulate the **TSH receptor** on the thyroid gland.
- This stimulation increases **thyroid hormone** production, leading to feedback inhibition that **suppresses TSH** levels, which is a common physiological finding in early pregnancy and **hyperemesis gravidarum**.
*Pre-existing Graves disease unmasked by pregnancy*
- Graves disease is caused by **thyroid-stimulating immunoglobulins (TSI)** and would typically present with a **goiter** or **ophthalmopathy**, which are absent here.
- The patient has no personal or family history of **thyroid disease**, and her symptoms coincide specifically with the peak of **hCG production**.
*Twin pregnancy with pathologic thyroid hormone elevation*
- While **twin pregnancies** result in higher hCG levels and greater TSH suppression, the term "pathologic" is incorrect as this is a **physiologic cross-reactivity**.
- There is no clinical evidence provided (like ultrasound) to confirm a **multiple gestation**, and single pregnancies with high hCG can cause the same laboratory profile.
*Hyperemesis gravidarum with secondary hyperthyroidism*
- While this patient has nausea and vomiting, **gestational thyrotoxicosis** is the mechanism causing the biochemical changes, rather than the vomiting causing the thyroid shift.
- Hyperemesis is a **clinical diagnosis** of severe vomiting; the question asks to explain the hormone findings using understanding of **pregnancy hormones** (hCG/TSH relationship).
*Thyroid adenoma with autonomous function*
- A toxic **thyroid adenoma** would typically present as a **palpable nodule** and function independently of pregnancy hormones.
- Autonomous function does not explain the correlation with high **hCG levels** at 8 weeks gestation, which is the hallmark of **physiologic thyrotoxicosis**.
Question 10: A 28-year-old woman presents to the clinic for evaluation of infertility. Her menstrual cycles have been regular every 28 days. She reports using basal body temperature charting, which shows a biphasic pattern with temperature elevation occurring around day 14. Serum progesterone is measured on day 21 of her cycle and is found to be 18 ng/mL (normal luteal phase >10 ng/mL). Based on this information, what is the most likely status of her ovulatory function?
A. Anovulatory cycles with inadequate corpus luteum function
B. Luteinized unruptured follicle syndrome
C. Normal ovulation with adequate luteal phase (Correct Answer)
D. Premature ovarian insufficiency
E. Polycystic ovary syndrome with irregular ovulation
Explanation: ***Normal ovulation with adequate luteal phase***
- A **serum progesterone level >10 ng/mL** on day 21 and a **biphasic basal body temperature** are definitive markers of successful ovulation.
- **Regular 28-day cycles** and a temperature shift around day 14 further confirm the presence of a functional **corpus luteum** and adequate luteal phase duration.
*Anovulatory cycles with inadequate corpus luteum function*
- **Anovulatory cycles** would lack the **biphasic temperature pattern** and typically present with irregular, unpredictable menstrual bleeding.
- Inadequate luteal function would result in **progesterone levels <10 ng/mL** during the mid-luteal phase, which is not the case here.
*Luteinized unruptured follicle syndrome*
- While this condition involves **luteinization** of a follicle without egg release, it is a rare cause of infertility and hard to diagnose with simple labs.
- Since the patient has all clinical indicators of **normal ovulatory physiology**, this specific pathology is less likely than a normal status.
*Premature ovarian insufficiency*
- This condition is characterized by **amenorrhea** or oligomenorrhea and elevated **FSH levels**, not regular 28-day cycles.
- Patients would typically show **low progesterone** and low estrogen due to follicular depletion, which contradicts the mid-luteal progesterone of 18 ng/mL.
*Polycystic ovary syndrome with irregular ovulation*
- **PCOS** usually presents with **oligomenorrhea** or amenorrhea and clinical or biochemical signs of **hyperandrogenism**.
- The patient’s highly **regular menstrual cycles** and confirmed mid-luteal progesterone elevation effectively rule out the chronic anovulation seen in PCOS.
